ID   haNK
AC   CVCL_IM23
SY   high affinity NK; CD16-V158.NK-92.05
DR   Wikidata; Q54872409
RX   PubMed=27861156;
WW   https://brinkbiologics.com/platform/
CC   Population: Caucasian.
CC   Characteristics: No longer dependent on IL2.
CC   Transfected with: HGNC; 3619; FCGR3A (with p.Phe176Val).
CC   Transfected with: HGNC; 6001; IL2.
CC   Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and non-commercial suppliers for this cell line. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: Natural killer cell; CL=CL_0000623.
DI   NCIt; C82217; Natural killer cell lymphoblastic leukemia/lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2142 ! NK-92
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 01-12-16; Last updated: 05-10-23; Version: 9
//
RX   PubMed=27861156; DOI=10.18632/oncotarget.13411;
RA   Jochems C., Hodge J.W., Fantini M., Fujii R., Morillon Y.M. II,
RA   Greiner J.W., Padget M.R., Tritsch S.R., Tsang K.-Y., Campbell K.S.,
RA   Klingemann H.-G., Boissel L., Rabizadeh S., Soon-Shiong P., Schlom J.;
RT   "An NK cell line (haNK) expressing high levels of granzyme and
RT   engineered to express the high affinity CD16 allele.";
RL   Oncotarget 7:86359-86373(2016).
//